$0.4395
0.0159[3.75%]
At close: Apr 26
$0.4395
0[0.00%]
After Hours: 5:57PM EDT
Cadrenal Therapeutics
(NASDAQ:CVKD)Cadrenal Therapeutics Stock (NASDAQ:CVKD), Analyst Ratings, Price Targets, Predictions
Cadrenal Therapeutics Inc has a consensus price target of $3.5, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Noble Capital Markets, and HC Wainwright & Co. on March 14, 2024, December 18, 2023, and November 20, 2023. With an average price target of $3.33 between HC Wainwright & Co., Noble Capital Markets, and HC Wainwright & Co., there's an implied 658.44% upside for Cadrenal Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Noble Capital Markets
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cadrenal Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/14/2024 | CVKD | Buy Now | Cadrenal Therapeutics | $0.44 | 582.59% | HC Wainwright & Co. | Joseph Pantginis | → $3 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | CVKD | Buy Now | Cadrenal Therapeutics | $0.44 | 810.13% | Noble Capital Markets | Robert LeBoyer | → $4 | Initiates | → Outperform | Get Alert |
| 11/20/2023 | CVKD | Buy Now | Cadrenal Therapeutics | $0.44 | 582.59% | HC Wainwright & Co. | Joseph Pantginis | → $3 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cadrenal Therapeutics (CVKD)?
The latest price target for Cadrenal Therapeutics (NASDAQ: CVKD) was reported by HC Wainwright & Co. on March 14, 2024. The analyst firm set a price target for $3.00 expecting CVKD to rise to within 12 months (a possible 582.59% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cadrenal Therapeutics (CVKD)?
The latest analyst rating for Cadrenal Therapeutics (NASDAQ: CVKD) was provided by HC Wainwright & Co., and Cadrenal Therapeutics reiterated their buy rating.
When was the last upgrade for Cadrenal Therapeutics (CVKD)?
There is no last upgrade for Cadrenal Therapeutics.
When was the last downgrade for Cadrenal Therapeutics (CVKD)?
There is no last downgrade for Cadrenal Therapeutics.
When is the next analyst rating going to be posted or updated for Cadrenal Therapeutics (CVKD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cadrenal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cadrenal Therapeutics was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
Is the Analyst Rating Cadrenal Therapeutics (CVKD) correct?
While ratings are subjective and will change, the latest Cadrenal Therapeutics (CVKD) rating was a reiterated with a price target of $0.00 to $3.00. The current price Cadrenal Therapeutics (CVKD) is trading at is $0.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.